{"drugs":["Lixisenatide"],"mono":{"0":{"id":"930797-s-0","title":"Generic Names","mono":"Lixisenatide"},"1":{"id":"930797-s-1","title":"Dosing and Indications","sub":{"0":{"id":"930797-s-1-4","title":"Adult Dosing","mono":"<ul><li>Lixisenatide has centralized marketing authorization by the European Medicines Agency (EMA) for use in the European Union (EU).<\/li><li><b>Type 2 diabetes mellitus:<\/b> initial, 10 mcg SUBQ once daily for 14 days; maintenance, 20 mcg SUBQ once daily starting on day 15; administer within the hour prior to the first meal of the day or the evening meal (European Medicines Agency-approved dosing)<\/li><li><b>Type 2 diabetes mellitus:<\/b> missed dose, administer SUBQ within the hour prior to the next meal (European Medicines Agency-approved dosing)<\/li><\/ul>"},"2":{"id":"930797-s-1-6","title":"Dose Adjustments","mono":"<ul><li><b>renal impairment:<\/b> mild (CrCl, 50 to 80 mL\/min), no dose adjustment required; moderate (CrCl, 30 to 50 mL\/min), use additional caution; severe (CrCl, less than 30 mL\/min) or ESRD, use not recommended<\/li><li><b>hepatic impairment:<\/b> no dose adjustment is required<\/li><li><b>geriatrics:<\/b> no dose adjustment necessary based on age<\/li><\/ul>"},"3":{"id":"930797-s-1-7","title":"Indications","mono":"<b>Non-FDA Labeled Indications<\/b><br\/>Type 2 diabetes mellitus<br\/>"}}},"3":{"id":"930797-s-3","title":"Contraindications\/Warnings","sub":[{"id":"930797-s-3-9","title":"Contraindications","mono":"hypersensitivity to lixisenatide, metacresol, or any component of the product <br\/>"},{"id":"930797-s-3-10","title":"Precautions","mono":"<ul><li>concomitant oral drugs with a narrow therapeutic index, or requiring rapid gastric absorption or careful clinical monitoring; absorption may be reduced; dosage adjustment may be required<\/li><li>concomitant use with both basal insulin and sulfonylurea not recommended; increased risk of hypoglycemia<\/li><li>dehydration may occur following gastrointestinal adverse reactions (eg, nausea, vomiting, diarrhea); avoid fluid depletion<\/li><li>diabetes ketoacidosis; avoid use<\/li><li>diabetes mellitus type 1; avoid use<\/li><li>gastrointestinal disease, severe (eg, severe gastroparesis); use not recommended<\/li><li>hypoglycemia; increased risk with concomitant use of basal insulin or sulfonylurea; dose reduction of concomitant medication may be required; monitoring recommended<\/li><li>pancreatitis, history of; acute pancreatitis has occurred with use of glucagon-like peptide-1 receptor agonists; discontinue use if acute pancreatitis suspected and do not restart if confirmed<\/li><li>renal impairment, severe (ie, CrCl less than 30 mL\/min), or end-stage renal disease; use not recommended<\/li><\/ul>"},{"id":"930797-s-3-11","title":"Pregnancy Category","mono":"Fetal risk cannot be ruled out. (TH)<br\/>"},{"id":"930797-s-3-12","title":"Breast Feeding","mono":"Micromedex: Infant risk cannot be ruled out.<br\/>"}]},"4":{"id":"930797-s-4","title":"Drug Interactions","sub":{"1":{"id":"930797-s-4-14","title":"Major","mono":"<ul><li>Amisulpride (theoretical)<\/li><li>Aripiprazole (theoretical)<\/li><li>Asenapine (theoretical)<\/li><li>Atazanavir (theoretical)<\/li><li>Clozapine (theoretical)<\/li><li>Darunavir (theoretical)<\/li><li>Fosamprenavir (theoretical)<\/li><li>Iloperidone (theoretical)<\/li><li>Indinavir (theoretical)<\/li><li>Lanreotide (theoretical)<\/li><li>Lopinavir (theoretical)<\/li><li>Lurasidone (theoretical)<\/li><li>Nelfinavir (theoretical)<\/li><li>Octreotide (theoretical)<\/li><li>Olanzapine (theoretical)<\/li><li>Paliperidone (theoretical)<\/li><li>Pasireotide (theoretical)<\/li><li>Quetiapine (theoretical)<\/li><li>Risperidone (theoretical)<\/li><li>Ritonavir (theoretical)<\/li><li>Saquinavir (theoretical)<\/li><li>Sertindole (theoretical)<\/li><li>Telaprevir (theoretical)<\/li><li>Tipranavir (theoretical)<\/li><li>Ziprasidone (theoretical)<\/li><li>Zotepine (theoretical)<\/li><\/ul>"},"2":{"id":"930797-s-4-15","title":"Moderate","mono":"<ul><li>Acebutolol (probable)<\/li><li>Acenocoumarol (probable)<\/li><li>Acetaminophen (probable)<\/li><li>Atenolol (probable)<\/li><li>Betaxolol (probable)<\/li><li>Bisoprolol (probable)<\/li><li>Carteolol (probable)<\/li><li>Carvedilol (probable)<\/li><li>Celiprolol (probable)<\/li><li>Dicumarol (probable)<\/li><li>Esmolol (probable)<\/li><li>Furazolidone (probable)<\/li><li>Insulin (probable)<\/li><li>Insulin Aspart, Recombinant (probable)<\/li><li>Insulin Bovine (probable)<\/li><li>Insulin Degludec (probable)<\/li><li>Insulin Detemir (probable)<\/li><li>Insulin Glulisine (probable)<\/li><li>Insulin Lispro, Recombinant (probable)<\/li><li>Iproniazid (probable)<\/li><li>Isocarboxazid (probable)<\/li><li>Labetalol (probable)<\/li><li>Levobunolol (probable)<\/li><li>Linezolid (probable)<\/li><li>Methylene Blue (probable)<\/li><li>Metipranolol (probable)<\/li><li>Metoprolol (probable)<\/li><li>Moclobemide (probable)<\/li><li>Nadolol (probable)<\/li><li>Nebivolol (probable)<\/li><li>Nialamide (probable)<\/li><li>Oxprenolol (probable)<\/li><li>Penbutolol (probable)<\/li><li>Phenelzine (probable)<\/li><li>Phenprocoumon (probable)<\/li><li>Pindolol (probable)<\/li><li>Practolol (probable)<\/li><li>Procarbazine (probable)<\/li><li>Propranolol (probable)<\/li><li>Rasagiline (probable)<\/li><li>Selegiline (probable)<\/li><li>Sotalol (probable)<\/li><li>Timolol (probable)<\/li><li>Tranylcypromine (probable)<\/li><li>Warfarin (probable)<\/li><\/ul>"}}},"5":{"id":"930797-s-5","title":"Adverse Effects","mono":"<b>Common<\/b><ul><li><b>Endocrine metabolic:<\/b>Hypoglycemia (combination therapy, 3.4% to 47.2%; monotherapy, 1.7%)<\/li><li><b>Gastrointestinal:<\/b>Diarrhea (10% or greater), Nausea (26.1%), Vomiting (10.5%)<\/li><li><b>Neurologic:<\/b>Headache (10% or greater)<\/li><\/ul><b>Serious<\/b><ul><li><b>Cardiovascular:<\/b>Heart failure (0.1%)<\/li><li><b>Immunologic:<\/b>Anaphylaxis (0.2%)<\/li><\/ul>"},"6":{"id":"930797-s-6","title":"Drug Name Info","sub":{"2":{"id":"930797-s-6-19","title":"Class","mono":"<ul><li>Endocrine-Metabolic Agent<\/li><li>Glucagon-Like Peptide-1 Receptor Agonist<\/li><\/ul>"},"3":{"id":"930797-s-6-20","title":"Regulatory Status","mono":"RX<br\/>"}}},"7":{"id":"930797-s-7","title":"Mechanism Of Action","mono":"Lixisenatide is a selective glucagon-like peptide-1 (GLP-1) receptor agonist that acts as an incretin mimetic agent to enhance glucose-dependent insulin secretion from the pancreatic beta cells. Therapeutic actions of lixisenatide, via the mechanisms involving cyclic AMP and\/or other intracellular signaling pathways, have included enhancement of insulin secretion  (glucose-dependent), glucose-dependent suppression of inappropriately high glucagon secretion, and slowing of gastric emptying. In type 2 diabetic patients, lixisenatide improves glycemic control by reducing fasting and postprandial glucose concentrations.<br\/>"},"8":{"id":"930797-s-8","title":"Pharmacokinetics","sub":[{"id":"930797-s-8-23","title":"Absorption","mono":"Tmax, SubQ: 1 to 3.5 hours <br\/>"},{"id":"930797-s-8-24","title":"Distribution","mono":"<ul><li>Protein binding: 55%<\/li><li>Vd: 100 L<\/li><\/ul>"},{"id":"930797-s-8-25","title":"Metabolism","mono":"metabolic degradation <br\/>"},{"id":"930797-s-8-26","title":"Excretion","mono":"<ul><li>Renal clearance: extensive<\/li><li>Total body clearance: 35 L\/hour<\/li><\/ul>"},{"id":"930797-s-8-27","title":"Elimination Half Life","mono":"3 hours <br\/>"}]},"9":{"id":"930797-s-9","title":"Administration","mono":"<ul><li><b>General Information<\/b><br\/>For subQ injection into the thigh, abdomen, or upper arm only; do not administer IV or IM<br\/><\/li><li><b>Subcutaneous<\/b><br\/><ul><li>available in 10-mcg and 20-mcg solution for injection in prefilled disposable pens and in a treatment initiation pack; 29- to 32-gauge needles not included<\/li><li>store refrigerated; after first use, store at room temperature and use within 14 days; do not store with needle attached to the pen; cap the pen to protect from light<\/li><li>do not mix with other injectable drugs<\/li><li>administer within an hour before any meal of the day; administer with the same meal every day if possible<\/li><li>administer oral gastroresistant formulations sensitive to stomach degradation, oral antibiotics, or other oral medications requiring a threshold concentration for efficacy 1 hour before or 4 hours following lixisenatide injection<\/li><\/ul><\/li><\/ul>"},"10":{"id":"930797-s-10","title":"Monitoring","mono":"improvements in fasting blood glucose and HbA1c levels are indicative of efficacy<br\/>"},"13":{"id":"930797-s-13","title":"Clinical Teaching","mono":"<ul><li>Advise patient to contact their healthcare provider immediately if symptoms of pancreatitis develop, such as persistent and\/or severe abdominal pain.<\/li><li>Direct patient to report symptoms of hypoglycemia and to avoid hypoglycemia while driving and using machines, particularly with coadministration of a basal insulin or a sulfonylurea.<\/li><li>Advise patient to contact their healthcare provider immediately if symptoms of anaphylaxis occur.<\/li><li>Side effects may include nausea, vomiting, or diarrhea.<\/li><li>Severe hypoglycemia may occur, particularly when used in combination with a basal insulin or a sulfonylurea.<\/li><li>Direct patient to maintain adequate hydration to prevent dehydration if nausea, vomiting, or diarrhea occur.<\/li><li>Advise patient that blood glucose self-monitoring is necessary when used in combination with a sulfonylurea or a basal insulin to adjust the dose of the concomitant drug.<\/li><li>Tell patient to inject drug within the hour before the first meal of the day or within the hour before the evening meal.<\/li><li>Advise patient to inject drug in the abdomen, thigh, or upper arm.<\/li><li>Direct patient to inject drug within the hour before the next meal if they miss a dose. Do not double the dose.<\/li><\/ul>"}}}